KIT D816V and the cytokine storm in mastocytosis: production and role of interleukin-6.
作者信息
Valent Peter
机构信息
Department of Internal Medicine I, Division of Hematology and Hemostaseology
Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria.
出版信息
Haematologica. 2020 Jan;105(1):5-6. doi: 10.3324/haematol.2019.234864.
Abstract
摘要
相似文献
1
KIT D816V and the cytokine storm in mastocytosis: production and role of interleukin-6.KIT D816V与肥大细胞增多症中的细胞因子风暴：白细胞介素-6的产生及作用
Haematologica. 2020 Jan;105(1):5-6. doi: 10.3324/haematol.2019.234864.
2
A new humanized in vivo model of KIT D816V+ advanced systemic mastocytosis monitored using a secreted luciferase.一种使用分泌型荧光素酶监测的KIT D816V+晚期系统性肥大细胞增多症的新型人源化体内模型。
Oncotarget. 2016 Dec 13;7(50):82985-83000. doi: 10.18632/oncotarget.12824.
3
Circulating KIT D816V mutation-positive non-mast cells in peripheral blood are characteristic of indolent systemic mastocytosis.外周血中循环的 KIT D816V 突变阳性非肥大细胞是惰性系统性肥大细胞增多症的特征。
Eur J Haematol. 2012 Jul;89(1):42-6. doi: 10.1111/j.1600-0609.2012.01789.x. Epub 2012 Apr 28.
4
Kit Mutations: New Insights and Diagnostic Value.试剂盒突变：新见解与诊断价值
Immunol Allergy Clin North Am. 2018 Aug;38(3):411-428. doi: 10.1016/j.iac.2018.04.005. Epub 2018 Jun 9.
5
Histone deacetylase inhibitor SAHA mediates mast cell death and epigenetic silencing of constitutively active D816V KIT in systemic mastocytosis.组蛋白去乙酰化酶抑制剂SAHA介导系统性肥大细胞增多症中组成型激活的D816V KIT的肥大细胞死亡和表观遗传沉默。
Oncotarget. 2017 Feb 7;8(6):9647-9659. doi: 10.18632/oncotarget.14181.
6
A transgenic zebrafish model expressing KIT-D816V recapitulates features of aggressive systemic mastocytosis.表达KIT-D816V的转基因斑马鱼模型概括了侵袭性系统性肥大细胞增多症的特征。
Br J Haematol. 2014 Oct;167(1):48-61. doi: 10.1111/bjh.12999. Epub 2014 Jul 2.
7
KIT D816V mutation burden does not correlate to clinical manifestations of indolent systemic mastocytosis.KIT D816V 突变负担与惰性系统性肥大细胞增多症的临床表现无关。
J Allergy Clin Immunol. 2013 Sep;132(3):723-728. doi: 10.1016/j.jaci.2013.02.019. Epub 2013 Apr 12.
8
Serum tryptase correlates with the KIT D816V mutation burden in adults with indolent systemic mastocytosis.血清类胰蛋白酶与惰性系统性肥大细胞增多症成人的 KIT D816V 突变负担相关。
Eur J Haematol. 2013 Aug;91(2):106-11. doi: 10.1111/ejh.12128. Epub 2013 Jun 28.
9
Analysis of the lineage relationship between mast cells and basophils using the c-kit D816V mutation as a biologic signature.利用c-kit D816V突变作为生物学标记分析肥大细胞和嗜碱性粒细胞之间的谱系关系。
J Allergy Clin Immunol. 2005 Jun;115(6):1155-61. doi: 10.1016/j.jaci.2005.02.030.
10
KIT D816V mutation-positive cell fractions in lesional skin biopsies from adults with systemic mastocytosis.成人系统性肥大细胞增多症患者皮损皮肤活检中 KIT D816V 突变阳性细胞比例。
Dermatology. 2013;226(3):233-7. doi: 10.1159/000349986. Epub 2013 Jun 14.
引用本文的文献
1
Diffuse Cutaneous Mastocytosis: A Current Understanding of a Rare Disease.弥漫性皮肤肥大细胞增生症：一种罕见疾病的当前认识。
Int J Mol Sci. 2024 Jan 23;25(3):1401. doi: 10.3390/ijms25031401.
2
Mastocytosis and Skin Cancer: The Current State of Knowledge.肥大细胞病与皮肤癌：当前知识状况。
Int J Mol Sci. 2023 Jun 7;24(12):9840. doi: 10.3390/ijms24129840.
3
Genetic Variants Leading to Urticaria and Angioedema and Associated Biomarkers.导致荨麻疹和血管性水肿的遗传变异及其相关生物标志物。
J Allergy Clin Immunol Pract. 2023 Aug;11(8):2286-2301. doi: 10.1016/j.jaip.2023.05.031. Epub 2023 May 30.
4
Secretory and Membrane-Associated Biomarkers of Mast Cell Activation and Proliferation.分泌型和膜相关生物标志物在肥大细胞激活和增殖中的作用。
Int J Mol Sci. 2023 Apr 11;24(8):7071. doi: 10.3390/ijms24087071.
5
The Role of Mast Cells in the Induction and Maintenance of Inflammation in Selected Skin Diseases.肥大细胞在某些皮肤疾病中炎症的诱导和维持中的作用。
Int J Mol Sci. 2023 Apr 10;24(8):7021. doi: 10.3390/ijms24087021.
6
Altered innate immune profile in blood of systemic mastocytosis patients.系统性肥大细胞增多症患者血液中先天性免疫特征的改变。
Clin Transl Allergy. 2022 Jun 14;12(6):e12167. doi: 10.1002/clt2.12167. eCollection 2022 Jun.
7
Malnutrition is associated with hyperinflammation and immunosuppression in COVID-19 patients: A prospective observational study.营养不良与 COVID-19 患者的过度炎症和免疫抑制有关：一项前瞻性观察研究。
Nutr Clin Pract. 2021 Aug;36(4):863-871. doi: 10.1002/ncp.10679. Epub 2021 May 12.
8
Molecular Background, Clinical Features and Management of Pediatric Mastocytosis: Status 2021.儿童肥大细胞增生症的分子背景、临床特征和治疗管理：2021 年现状。
Int J Mol Sci. 2021 Mar 4;22(5):2586. doi: 10.3390/ijms22052586.
9
Mast Cell and Eosinophil Activation Are Associated With COVID-19 and TLR-Mediated Viral Inflammation: Implications for an Anti-Siglec-8 Antibody.肥大细胞和嗜酸性粒细胞的激活与 COVID-19 及 TLR 介导的病毒炎症相关：抗 Siglec-8 抗体的影响。
Front Immunol. 2021 Mar 10;12:650331. doi: 10.3389/fimmu.2021.650331. eCollection 2021.
10
Clinical Impact of Inherited and Acquired Genetic Variants in Mastocytosis.肥大细胞增多症中遗传和获得性基因突变的临床影响。
Int J Mol Sci. 2021 Jan 2;22(1):411. doi: 10.3390/ijms22010411.
本文引用的文献
1
Multidisciplinary Challenges in Mastocytosis and How to Address with Personalized Medicine Approaches.肥大细胞增多症的多学科挑战及如何采用个体化医学方法应对。
Int J Mol Sci. 2019 Jun 18;20(12):2976. doi: 10.3390/ijms20122976.
2
Oncogenic D816V-KIT signaling in mast cells causes persistent IL-6 production.肥大细胞中致癌性D816V-KIT信号传导导致白细胞介素-6持续产生。
Haematologica. 2020 Jan;105(1):124-135. doi: 10.3324/haematol.2018.212126. Epub 2019 Apr 4.
3
Inhibitory effects of midostaurin and avapritinib on myeloid progenitors derived from patients with KIT D816V positive advanced systemic mastocytosis.米哚妥林和 avapritinib 对 KIT D816V 阳性晚期系统性肥大细胞增多症患者来源的髓系祖细胞的抑制作用。
Leukemia. 2019 May;33(5):1195-1205. doi: 10.1038/s41375-019-0450-8. Epub 2019 Mar 25.
4
Preclinical human models and emerging therapeutics for advanced systemic mastocytosis.用于晚期系统性肥大细胞增多症的临床前人类模型和新兴治疗方法。
Haematologica. 2018 Nov;103(11):1760-1771. doi: 10.3324/haematol.2018.195867. Epub 2018 Jul 5.
5
Mast cells as sources of cytokines, chemokines, and growth factors.肥大细胞作为细胞因子、趋化因子和生长因子的来源。
Immunol Rev. 2018 Mar;282(1):121-150. doi: 10.1111/imr.12634.
6
Midostaurin: a magic bullet that blocks mast cell expansion and activation.米哚妥林：一种阻断肥大细胞扩增和激活的“神奇子弹”。
Ann Oncol. 2017 Oct 1;28(10):2367-2376. doi: 10.1093/annonc/mdx290.
7
Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts.肥大细胞增多症：2016年世界卫生组织更新分类及新出现的治疗理念。
Blood. 2017 Mar 16;129(11):1420-1427. doi: 10.1182/blood-2016-09-731893. Epub 2016 Dec 28.
8
Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis.中剂量伊马替尼治疗晚期系统性肥大细胞增多症的疗效和安全性。
N Engl J Med. 2016 Jun 30;374(26):2530-41. doi: 10.1056/NEJMoa1513098.
9
Cytokine Regulation of Microenvironmental Cells in Myeloproliferative Neoplasms.骨髓增殖性肿瘤中微环境细胞的细胞因子调节
Mediators Inflamm. 2015;2015:869242. doi: 10.1155/2015/869242. Epub 2015 Oct 12.
10
Mast Cells, Mastocytosis, and Related Disorders.肥大细胞、肥大细胞增多症及相关疾病
N Engl J Med. 2015 Jul 9;373(2):163-72. doi: 10.1056/NEJMra1409760.
Zotero 插件